USP22 transcriptional activity is negatively regulated by the histone deacetylase inhibitor trichostatin A

Mol Med Rep. 2014 Dec;10(6):3343-7. doi: 10.3892/mmr.2014.2666. Epub 2014 Oct 15.

Abstract

The ubiquitin‑specific protease 22 (USP22) gene is overexpressed in the majority of types of cancer cells, and has been implicated in tumorigenesis. However, the mechanisms that regulate its expression remain unclear. The results of the present study demonstrated that the expression of USP22 is negatively regulated by trichostatin A (TSA), a classical histone deacetylase inhibitor. Furthermore, TSA was revealed to interfere with the binding of RNA polymerase II to the USP22 promoter, directly suppressing its transcription. In addition, the overexpression of USP22 was observed to attenuate TSA‑induced apoptosis in HeLa cells. To the best of our knowledge, these results provide the first insight into the regulation of the USP22 gene by antitumor drugs and into the mechanisms underlying the anticancer activity of TSA.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Cell Line, Tumor
  • HeLa Cells
  • Histone Deacetylase Inhibitors / pharmacology*
  • Humans
  • Hydroxamic Acids / pharmacology*
  • Promoter Regions, Genetic / drug effects
  • Promoter Regions, Genetic / genetics
  • RNA Polymerase II / genetics*
  • Thiolester Hydrolases / genetics*
  • Transcription, Genetic / drug effects*
  • Transcription, Genetic / genetics
  • Ubiquitin Thiolesterase

Substances

  • Antineoplastic Agents
  • Histone Deacetylase Inhibitors
  • Hydroxamic Acids
  • trichostatin A
  • RNA Polymerase II
  • Thiolester Hydrolases
  • Ubiquitin Thiolesterase
  • Usp22 protein, human